Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene
| Autor: | Lisa Y. Zhou, Joel W. Neal, Li Zhou, Cheryl D. Cho-Phan, Nathaniel J. Myall, Henning Stehr, Maximilian Diehn, Heather A. Wakelee |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology Male Proto-Oncogene Proteins B-raf Cancer Research medicine.medical_specialty Indoles Lung Neoplasms medicine.medical_treatment Disease Adenocarcinoma Targeted therapy 03 medical and health sciences Erlotinib Hydrochloride 0302 clinical medicine Internal medicine Carcinoma Non-Small-Cell Lung medicine Humans Molecular Targeted Therapy Precision Medicine Vemurafenib Lung cancer Aged Sulfonamides Oncogene business.industry medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis Mutation Cancer research Disease Progression Erlotinib business V600E medicine.drug |
| Zdroj: | Clinical lung cancer. 17(2) |
| ISSN: | 1938-0690 |
| Popis: | Long-term survival is uncommon in advanced-stage nonesmall-cell lung cancer (NSCLC). The effect of driver mutations on the clinical course is an area of ongoing study, in particular, for less common mutations such as those occurring in the BRAF oncogene. We present the case of a 75-year-old man with no smoking history who was diagnosed with an EGFR wild-type, V600E BRAF-mutant lung adenocarcinoma. Despite presenting with disease in multiple lung lobes and progression to pleural involvement, the patient achieved ongoing survival lasting more than 9 years. The patient’s course was remarkable for an initially unclear molecular tumor profile but stable disease with erlotinib therapy despite having no mutations in the EGFR oncogene. The patient subsequently achieved a prolonged clinical and radiographic response to vemurafenib, a targeted BRAF inhibitor. Molecular profiling using nextgeneration cancer personalized profiling by deep sequencing ultimately provided an effective method for confirming the mutational status of the patient’s tumor at multiple points in his disease course. Although V600E mutations in the BRAF oncogene have not been commonly associated with long-term survival, the findings from the present case suggest that such mutations might be compatible with slow disease progression in some patients. The use of targeted therapy in the treatment of V600E BRAF-mutant NSCLC might contribute to long survival for these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect